Category

Pharmaceutical 3504 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Plaintiffs attorneys say transvaginal mesh victims should not have to prove their injuries

transvaginal mesh

Johnson & Johnson’s request that plaintiffs in a multidistrict litigation (MDL) who allege the company’s transvaginal mesh was defective prove they were injured is ludicrous and nothing more than a delay tactic, plaintiffs attorneys said responding to a Jan. 13 motion by the consumer health care and pharmaceutical giant. Johnson & Johnson and its subsidiary Ethicon Inc., asked that the near-24,000 plaintiffs in the multidistrict litigation prove thy were injured by the company’s transvaginal mesh, and asked the court to require every plaintiff’s attorney to answer under oath certain questions on how plaintiffs were solicited. The companies claim that “unscrupulous” ... Read More

Janssen knew Risperdal could cause boys to grow breasts

risperdal

Johnson & Johnson unit Janssen Pharmaceuticals knew for years that its antipsychotic drug Risperdal could cause the abnormal growth of breasts in boys and young men, yet the company failed to warn the mother of an Alabama boy or his doctors of these “distressing results,” the mother’s attorney told a Philadelphia jury. “We’re going to show you that Janssen knew all the time that he took the drug that the drug caused an increase in prolactin levels, and that it was associated with children and adolescents having this distressing result,” the attorney said. Austin Pledger, now 20, was prescribed Risperdal ... Read More

Plaintiffs identify Philadelphia woman as model case for Zimmer knee implant lawsuit

Zimmer knee

Plaintiffs in a multidistrict litigation involving alleged defects with Zimmer knee implants asked an Illinois federal judge to select the case of a Philadelphia woman to serve as the first bellwether trial, claiming that the woman’s age, gender and implant type best represent plaintiffs’ issues with the implants. Ramona Diano, 72, had Zimmer LPS Flex Gender femoral components implanted in both knees. Both implants failed. Plaintiffs say that Diano is in the most common age group and gender for the procedure, and her case has the least individual issues among the other cases previously identified as possible bellwethers. Dinao’s lawsuit ... Read More

Bellwether cases soon to be selected for Mentor Corp transvaginal mesh

transvaginal mesh

A Georgia federal judge identified six possible bellwether cases out of hundreds accusing Johnson & Johnson unit Mentor Corp of not informing patients or doctors of the risks associated with its ObTape sling transvaginal mesh device used to treat urinary incontinence in women. U.S. District Judge Clay D. Land ordered the parties to select two of the six lawsuits within three weeks. The cases will be tried in October and November 2015. The lawsuits allege Mentor marketed the defective devices, which caused serious injuries to women. Mentor discontinued the implants in 2006. Transvaginal mesh is used to treat pelvic organ ... Read More

FDA approves new drug to treat plaque psoriasis

fda-logo

Federal drug regulators have approved Novartis AG’s new drug Cosentyx designed to dramatically improve symptoms of moderate-to-severe plaque psoriasis. The approval gives the Swiss pharmaceutical company first market share against competitors Eli Lilly & Co. and Amgen Inc., both of which are seeking approval for similar treatments. Psoriasis is is a skin condition that causes patches of skin redness and irritation. The most common form of the autoimmune disorder is plaque psoriasis, which causes patients to develop thick, red skin with flaky, silver-white patches called scales. An estimated 7.5 million Americans have psoriasis. Cosentyx contains the active ingredient secukinumab, an ... Read More

Judge rules $2 million verdict stands against transvaginal mesh maker

bladder sling

A federal judge denied a mistrial and left intact a $2 million jury verdict against medical device manufacturer C. R. Bard Inc., in a bellwether trial over claims that its transvaginal mesh implant was defective and caused serious injuries. U.S. District Judge Joseph R. Goodwin said the motion stood because the company had not proven a miscarriage of justice. However, Goodwin also did not find unconstitutional a provision in Georgia’s Tort Reform Act of 1987 that requires product liability plaintiffs to give up 75 percent of their punitive damage earnings to the state. This comes as a blow to plaintiffs Donna and ... Read More

Hospira recalls saline injection due to human hair contamination

Recalls - Hospira-logo

Hospira Inc., is issuing a nationwide recall of one lot of 0.9 % Sodium Chloride Injection due to one confirmed report of human hair floating sealed in a bag of the solution in the additive port area. To date, there have been no adverse event reports associated with this issue. The recall affects one lot of 0.9 % Sodium Chloride Injection, USP, 250 mL (NDC 0409-7983-02, Lot 44-002-JT, Expiry 1AUG2016). Sodium Chloride is a saline solution used in catheter flush injections or intravenous infusions. Injected particulate material may cause adverse events such as local inflammation, phlebitis, and/or low-level allergic response. ... Read More

Outbreak of drug-resistant superbug linked to specialized endoscopes

duodenoscope

A specialized endoscope, put into the throats of a half-million people each year to treat gallstones, cancers, and other digestive system problems, has been identified as the source of a deadly bacterial infection in patients who have undergone procedures using the devices. It was found that conventional methods of cleaning the specialized endoscopes, known as duodenoscopes, do not always remove the so-called superbug. If the bacteria is not thoroughly removed from the scopes, the devices can spread infections from patient to patient. The superbug, known as CRE, is highly resistant to numerous antibiotics and kills as many as 40 to 50 ... Read More

Coffee may help protect against deadly melanoma

viagra

People who drink four or more cups of coffee a day are 20 percent less likely to develop melanoma, the most deadly form of skin cancer, over 10 years, according to a new study published in the Journal of the National Cancer Institute. The benefit is only with caffeinated coffee and not decaf. The reason, researchers say, is that coffee contains numerous compounds that keep cancer-fighting processes that are triggered by UV light under control. The roasting process also causes coffee beans to release vitamin derivatives that have been shown to protect against UV damage in laboratory mice. There’s also some ... Read More

Long-term hormonal birth control use linked to rare brain tumors

mirena IUD

Women who use hormonal contraceptives for at least five years are at greater risk of developing a rare form of brain cancer known as glioma, a new study suggests. All forms of hormonal birth control contain estrogen, progestin or a combination of both hormones. These include birth control pills and patches, Mirena IUD, and NuvaRing. Gliomas are a very rare brain tumor with a very poor prognosis. Of the 10,000 patients diagnosed with malignant gliomas each year, only half are alive after one year, and only 25 percent survive two years. The study, published in the British Journal of Clinical ... Read More